合作者(3981)TOP 5
  • Thomas,GN
  • Critchley,JAJH
  • Hu,Miao
  • Chan,JCN
  • Chan,Paul
關 鍵 字
發文可能採用名字
  • Brian Tomlinson
  • 湯寧信
  • Tomlinson, Brian
  • Tomlinson, B
  • 汤宁信
  • Tomlinson, B.
  • Tomlinson B
  • Tomlinson B.
  • Tomlinson Brian
  • Tomlinson ,B.
  • Tomlinson B rian
  • Brian, Tomlinson
  • TOMLINSON, B

湯寧信

醫學院(FMD)

ORCID: 0000-0001-6717-5444

ResearcherID: AAD-9404-2019; P-5365-2015

成果: 770 件 | 合作者:3981 

WOS核心合集引用:16728 | H Index:61 | WOS收錄:605

CNKI收錄:15 | SCOPUS收錄:493

論文: 770

論文: 770 篇 上傳 編輯 糾錯 可能是湯寧信的文章 匯出

1.Advances in Dyslipidaemia Treatments: Focusing on ApoC3 and ANGPTL3 Inhibitors

Tomlinson, Brian, Wu     More...

Journal of Lipid and Atherosclerosis[2287-2892], Published 2024, Volume 13, Issue 1, Pages 2-20

收錄情况: SCOPUS

2.Circulating metabolomic markers linking diabetic kidney disease and incident cardiovascular disease in type 2 diabetes: analyses from the Hong Kong Diabetes Biobank

Jin, Q, Lau, ESH, Lu     More...

DIABETOLOGIA[0012-186X], Published 2024, Volume 67, Issue 5, Pages 837-849

收錄情况: WOS SCOPUS

WOS核心合集引用: 1  2023影響因子:  8.4 

3.Genetic drivers of heterogeneity in type 2 diabetes pathophysiology

    More...

NATURE[0028-0836], Published 2024, Volume 627, Issue 8003, Pages 347-357

收錄情况: WOS SCOPUS

WOS核心合集引用: 33  2023影響因子:  50.5 

4.Effects of glucose-lowering drugs on cardiovascular outcomes in patients with type 2 diabetes: an update

Tomlinson, B, Chan,     More...

EXPERT OPINION ON DRUG METABOLISM & TOXICOLOGY[1742-5255], Published 2024, Volume 20, Issue 4, Pages 175-179

收錄情况: WOS SCOPUS

WOS核心合集引用: 0  2023影響因子:  3.9 

5.The maximum dose of atorvastatin and simvastatin as well as rosuvastatin should be restricted in East Asians

Tomlinson, B, Chow,     More...

HONG KONG MEDICAL JOURNAL[1024-2708], Published 2024, Volume 30, Issue 2, Pages 184-185

收錄情况: WOS SCOPUS

WOS核心合集引用: 0  2023影響因子:  3.1 

6.Genetic factors related to aspirin resistance using the Multiplate® device in Hong Kong Chinese patients with stable coronary heart disease

Zeng, WW, Chu, TTW,     More...

HELIYON[2405-8440], Published 2024, Volume 10, Issue 14,

收錄情况: WOS SCOPUS

WOS核心合集引用: 0  2023影響因子:  3.4 

7.Therapeutic efficacy of ECs Foxp1 targeting Hif1α-Hk2 α-Hk2 glycolysis signal to restrict angiogenesis

Pi, JJ, Chang, H, Ch     More...

REDOX BIOLOGY[2213-2317], Published 2024, Volume 75,

收錄情况: WOS SCOPUS

WOS核心合集引用: 0  2023影響因子:  10.7 

8.Options for patients with out-of-control blood pressure: after all avenues have been exhausted

Zeng, WW, Tomlinson,     More...

EXPERT REVIEW OF CARDIOVASCULAR THERAPY[1477-9072], Published 2024,

收錄情况: WOS SCOPUS

WOS核心合集引用: 0  2023影響因子:  1.8 

9.Identification of a Common Variant for Coronary Heart Disease at PDE1A Contributes to Individualized Treatment Goals and Risk Stratification of Cardiovascular Complications in Chinese Patients With Type 2 Diabetes

Tam, Claudia H.T., L     More...

Diabetes care[1935-5548], Published 2023, Volume 46, Issue 6, Pages 1271-1281

收錄情况: WOS SCOPUS

WOS核心合集引用: 3 

10.Molecular mechanisms and therapeutic perspectives of peroxisome proliferator-activated receptor α agonists in cardiovascular health and disease

Pu, Yujie, Cheng, Ch     More...

Medicinal Research Reviews[0198-6325], Published 2023, Volume 43, Issue 6, Pages 2086-2114

收錄情况: WOS SCOPUS

WOS核心合集引用: 7  2023影響因子:  10.9  发表年影響因子:  10.9 

本系統需要使用 Internet Explorer 9.0 以上Firefox || Chrome瀏覽器

Copyright © 2018 澳門科技大學學者庫